Especially in the treatment of RCCs, significant improvements in response rates were seen with the introduction of therapeutic monoclonal antibodies (mAbs) against tumor immune checkpoint axes, which can be combined with each other and are often used in combination with pro-inflammatory cytokines or with receptor tyrosine kinase inhibitors for additive effects. Here, NTRK1 is linked to neoplasm.